BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 18217129)

  • 1. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
    Stasi R; Evangelista ML; Stipa E; Buccisano F; Venditti A; Amadori S
    Thromb Haemost; 2008 Jan; 99(1):4-13. PubMed ID: 18217129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
    Stasi R; Evangelista ML; Amadori S
    Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.
    Panzer S
    Vox Sang; 2008 Jan; 94(1):1-5. PubMed ID: 17973895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
    Nurden AT; Viallard JF; Nurden P
    Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New options after first-line therapy for chronic immune thrombocytopenic purpura.
    Burzynski J
    Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S11-21. PubMed ID: 19139486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positioning new treatments in the management of immune thrombocytopenia.
    Arnold DM
    Pediatr Blood Cancer; 2013; 60 Suppl 1(Suppl 1):S19-22. PubMed ID: 23109488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging strategies to treat chronic immune thrombocytopenic purpura.
    Newland A
    Eur J Haematol Suppl; 2008 Feb; (69):27-33. PubMed ID: 18211570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two new drugs for chronic ITP.
    Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses.
    Arnold DM; Nazi I; Kelton JG
    Expert Opin Investig Drugs; 2009 Jun; 18(6):805-19. PubMed ID: 19426124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New treatment options for primary immune thrombocytopenia].
    Gudbrandsdottir S; Frederiksen H; Birgens HS; Nielsen CH; Nielsen OJ; Stentoft J; Hasselbalch HC
    Ugeskr Laeger; 2011 Jan; 173(4):271-4. PubMed ID: 21262171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of chronic immune thrombocytopenic purpura. Looking for something better. Review].
    VizcaĆ­no G; Diez-Ewald M; VizcaĆ­no-Carruyo J
    Invest Clin; 2009 Mar; 50(1):95-108. PubMed ID: 19418731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
    Godeau B;
    Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
    [No Abstract]   [Full Text] [Related]  

  • 15. Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.
    Stasi R
    Expert Rev Hematol; 2008 Dec; 1(2):145-52. PubMed ID: 21082919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current therapies in primary immune thrombocytopenia.
    Pels SG
    Semin Thromb Hemost; 2011 Sep; 37(6):621-30. PubMed ID: 22102265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology and management of primary immune thrombocytopenia.
    Kashiwagi H; Tomiyama Y
    Int J Hematol; 2013 Jul; 98(1):24-33. PubMed ID: 23702914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura.
    Gernsheimer TB
    Hematology Am Soc Hematol Educ Program; 2008; ():219-26. PubMed ID: 19074086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic options for immune thrombocytopenia.
    Schipperus M; Fijnheer R
    Neth J Med; 2011; 69(11):480-5. PubMed ID: 22173361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current options for the treatment of idiopathic thrombocytopenic purpura.
    Arnold DM; Kelton JG
    Semin Hematol; 2007 Oct; 44(4 Suppl 5):S12-23. PubMed ID: 18096468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.